ArticleFoods (Basel, Switzerland)2026
The Mechanism of GABA in Attenuating Neuroinflammation in Alzheimer's Disease: CP/CEBPα/miR-34a-Mediated Suppression of HDAC2/3 in Astrocytes.
Article in Foods (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Potential Role of Red Yeast Rice in the Prevention and Treatment of Alzheimer's Disease.International journal of medical sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
As a widely available dietary supplement, γ-Aminobutyric acid (GABA) exhibits potential for early intervention against Alzheimer's disease (AD). This study demonstrates that GABA alleviates AD neuroinflammation, and its suppression of astrocytic pro-inflammatory cytokine expression through histone deacetylase (HDAC2/3) inhibition contributes to this effect. Here, in both the cerebral cortex of AD mice and Aβ-exposed U251 cells, pro-inflammatory cytokines and HDAC2/3 expression levels were elevated, whereas the levels of creatine phosphate (CP), CCAAT/enhancer-binding protein α (CEBPα) and microRNA34a (miR-34a) were decreased. GABA treatment counteracted these alterations. Silencing HDAC2 or HDAC3 suppressed pro-inflammatory cytokines. Transfection with miR-34a mimics suppressed pro-inflammatory cytokines and HDAC2/3 expression in U251 cells, while miR-34a inhibitors had the opposite effect. A luciferase reporter assay confirmed HDAC2 as a direct miR-34a target via 3'UTR binding. Knockdown of CEBPα suppressed miR-34a expression, thereby elevating HDAC2/3 and pro-inflammatory cytokine expression in U251 cells. In CP-treated U251 cells, CEBPα and miR-34a expression was elevated, while pro-inflammatory cytokine and HDAC2/3 expression was down-regulated. In conclusion, GABA alleviates neuroinflammation in AD model mice. This effect may be partially attributed to its suppression of astrocyte-derived pro-inflammatory cytokine expression via HDAC2/3 inhibition. The CP/CEBPα/miR-34a pathway mediates the inhibitory effect of GABA on HDAC2/3 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.